title: Reduction of adhesion formation by intraperitoneal administration of anti-inflammatory peptide 2.
abstract: Adhesion formation is a major source of postoperative morbidity and mortality. Therefore, the reduction of postoperative adhesion formation would be of clinical benefit. Various modalities have been shown to reduce adhesion formation, including fibrinolytic enzymes, nonsteroidal anti-inflammatory drugs, and barriers that reduce the apposition of sites of potential adhesion formation. This study examined the ability of a phospholipase A2 inhibitor, anti-inflammatory peptide 2 (antinflammin), to reduce the formation of intraperitoneal adhesions in two rabbit models of adhesion formation. In the sidewall model, antinflammin was administered via Alzet miniosmotic pump for the entire postoperative interval, and there was a dose-dependent reduction in the area of the sidewall injury that was involved in adhesions to the cecum and the bowel. In the double uterine horn model, antinflammin was administered via Alzet miniosmotic pump to the area of injury for either 1, 2, 3, or 7 days. Administration of antinflammin for as little as 24 h after surgery significantly reduced the extent of adhesion formation. Administration of the peptide for longer periods of time did not further increase the reduction in adhesion formation. These studies clearly demonstrate that postoperative administration of antinflammin to the site of injury reduced the formation of postoperative adhesions in two animal models.
authors.affiliation: University of Southern California, Department of Obstetrics and Gynecology, Livingston Research Center, Los Angeles 90033, USA.
authors.forename: K E
authors.initials: KE
authors.lastname: Rodgers
authors.forename: W
authors.initials: W
authors.lastname: Girgis
authors.forename: J D
authors.initials: JD
authors.lastname: Campeau
authors.forename: G S
authors.initials: GS
authors.lastname: diZerega
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D004195:Disease Models, Animal; D005260:Female; D007274:Injections, Intraperitoneal; D009842:Oligopeptides / Q000494:pharmacology*; D010446:Peptide Fragments / Q000494:pharmacology*; D010741:Phospholipases A / Q000037:antagonists & inhibitors*; D054467:Phospholipases A2; D011817:Rabbits; D000267:Tissue Adhesions / Q000517:prevention & control*; D014599:Uterus / Q000473:pathology / Q000601:surgery
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D009842:Oligopeptides; D010446:Peptide Fragments; C064647:antiflammin P2; D010741:Phospholipases A; D054467:Phospholipases A2